Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Forecasted to Earn Q1 2024 Earnings of ($0.20) Per Share

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) – Research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Cyclo Therapeutics in a research note issued on Wednesday, May 1st. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.20) for the quarter. HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.64) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.47) EPS and FY2027 earnings at ($0.38) EPS.

Cyclo Therapeutics (NASDAQ:CYTH) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.23) earnings per share for the quarter. Cyclo Therapeutics had a negative net margin of 1,864.03% and a negative return on equity of 4,506.97%. The company had revenue of $0.31 million during the quarter.

Separately, Ascendiant Capital Markets started coverage on Cyclo Therapeutics in a research report on Monday, April 22nd. They issued a “buy” rating and a $2.60 price target on the stock.

Cyclo Therapeutics Stock Up 2.7 %

Shares of NASDAQ CYTH opened at $1.51 on Friday. The business’s 50 day moving average is $1.46 and its two-hundred day moving average is $1.47. The company has a market cap of $43.37 million, a P/E ratio of -1.16 and a beta of -0.18. Cyclo Therapeutics has a 12 month low of $0.89 and a 12 month high of $2.57.

Institutional Trading of Cyclo Therapeutics

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund V Management LLC acquired a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics makes up about 80.8% of Founders Fund V Management LLC’s investment portfolio, making the stock its biggest holding. Founders Fund V Management LLC owned approximately 2.11% of Cyclo Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 68.55% of the company’s stock.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.